Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cough – Pipeline Review, H1 2017, provides an overview of the Cough (Respiratory) pipeline landscape.
Cough is a common reflex action that aims to clear the throat of mucus or foreign irritants. Dry cough, chronic cough and whooping cough (also known as pertussis) are distinct types of cough. Symptoms include runny or stuffy nose, hoarseness, wheezing and shortness of breath, heartburn or a sour taste in mouth and rarely coughing up blood. The predisposing factors include asthma, chronic obstructive pulmonary disease, cigarette smoking, lung diseases such as bronchiectasis, interstitial lung disease, or tumors, lung infections such as pneumonia or acute bronchitis and allergic rhino sinusitis. Treatment includes cough suppressants, oral expectorants, and topical (externally applied) drugs.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cough – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cough (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cough (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cough and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical, Discovery and Unknown stages are 2, 1, 6, 9, 2 and 4 respectively.
Cough (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cough (Respiratory).
- The pipeline guide reviews pipeline therapeutics for Cough (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cough (Respiratory) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cough (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cough (Respiratory)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cough (Respiratory).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cough (Respiratory) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Afferent Pharmaceuticals Inc
Alitair Pharmaceuticals Inc
Alveonix AG
AstraZeneca Plc
BELLUS Health Inc
Charleston Laboratories Inc
Conrig Pharma ApS
Daewoong Pharmaceutical Co Ltd
Hyundai Pharmaceutical Co Ltd
NeRRe Therapeutics Ltd
Orbis Biosciences Inc
Patara Pharma Inc
PhytoHealth Corp
Pila Pharma AB
Vernalis Plc
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Cough – Overview
Cough – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Cough – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cough – Companies Involved in Therapeutics Development
Afferent Pharmaceuticals Inc
Alitair Pharmaceuticals Inc
Alveonix AG
AstraZeneca Plc
BELLUS Health Inc
Charleston Laboratories Inc
Conrig Pharma ApS
Daewoong Pharmaceutical Co Ltd
Hyundai Pharmaceutical Co Ltd
NeRRe Therapeutics Ltd
Orbis Biosciences Inc
Patara Pharma Inc
PhytoHealth Corp
Pila Pharma AB
Vernalis Plc
Cough – Drug Profiles
AF-219 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ax-8 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
benzonatate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-5937 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-05 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-06 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-07 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCP-08 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLAT-313 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
codeine + guaifenesin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cromolyn sodium – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWJ-1340 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guaifenesin + hydrocodone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
guaifenesin ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lesogaberan – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levodropropizine CR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ORB-110 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
orvepitant maleate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PHCA-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-1226 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-015 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-016 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-018 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XEND-0501 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cough – Dormant Projects
Cough – Discontinued Products
Cough – Product Development Milestones
Featured News & Press Releases
Dec 21, 2016: FDA accepts CCP-08 NDA for full review
Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis
Sep 06, 2016: Vernalis annopunces that FDA accepts CCP-07 NDA for full review
Jul 08, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Multiple-Dose Comparative Bioavailability Study
May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference
May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors
Apr 25, 2016: Afferent Pharmaceuticals Announces Presentation of Chronic Cough Clinical Data at the Upcoming American Thoracic Society 2016 International Conference
Apr 14, 2016: Vernalis Announces Successful Completion of CCP-07 Pivotal Multiple-Dose Comparative Bioavailability Study
Apr 13, 2016: Vernalis Announces Successful Completion of CCP-08 Pivotal Single-Dose Comparative Bioavailability Study
Dec 21, 2015: Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study
Oct 12, 2015: Vernalis announces start of CCP-08 12 month stability testing
Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial
Jul 01, 2015: Spriaso Announces Approval of New Drug Application for the Long Acting Codeine Antitussive With a Popular Anti-Histamine
Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing
Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Cough, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Cough – Pipeline by Afferent Pharmaceuticals Inc, H1 2017
Cough – Pipeline by Alitair Pharmaceuticals Inc, H1 2017
Cough – Pipeline by Alveonix AG, H1 2017
Cough – Pipeline by AstraZeneca Plc, H1 2017
Cough – Pipeline by BELLUS Health Inc, H1 2017
Cough – Pipeline by Charleston Laboratories Inc, H1 2017
Cough – Pipeline by Conrig Pharma ApS, H1 2017
Cough – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2017
Cough – Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017
Cough – Pipeline by NeRRe Therapeutics Ltd, H1 2017
Cough – Pipeline by Orbis Biosciences Inc, H1 2017
Cough – Pipeline by Patara Pharma Inc, H1 2017
Cough – Pipeline by PhytoHealth Corp, H1 2017
Cough – Pipeline by Pila Pharma AB, H1 2017
Cough – Pipeline by Vernalis Plc, H1 2017
Cough – Dormant Projects, H1 2017
Cough – Dormant Projects, H1 2017 (Contd..1), H1 2017
Cough – Discontinued Products, H1 2017
List of Figures
Number of Products under Development for Cough, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
